e-Article
First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Document Type
Abstract
Author
Source
In Blood 23 November 2021 138 Supplement 1:3556-3556
Subject
Language
ISSN
0006-4971